$RANI

Rani Therapeutics Holdings, Inc. (RANI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001856725 0001856725 2026-08-01 2026-08-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1,

IMRAN MIR A purchased 36,000 shares of Rani Therapeutics Holdings, Inc. (RANI) at $0.69 on 2026-07-21.

Imran Talat (Chief Executive Officer) purchased 35,000 shares of Rani Therapeutics Holdings, Inc. (RANI) at $0.72 on 2026-07-17.

Rani Therapeutics (RANI) reported Phase 1a results for RT-114, an oral RaniPill capsule delivering PG-102, a GLP-1/GLP-2 dual agonist from ProGen. In 30 healthy volunteers, oral RT-114 produced >150% systemic exposure vs 12 mg subcutaneous, with similar half-life (5.6 vs 5.3 days) and no serious adverse events. Phase 1b is underway; data expected in 2027.

Rani Therapeutics (Nasdaq: RANI) said it entered an R&D collaboration with PegBio to use RaniPill to develop oral formulations of multiple PegBio obesity and metabolic disease candidates. The work will focus on preclinical development with the aim of moving selected molecules into clinical testing. Rani also cited its Phase 1 RT-114 GLP-1/GLP-2 dual agonist and other preclinical obesity candidates.

Rani Therapeutics Holdings, Inc. (RANI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.2 3 rani-ex10_2.htm EX-10.2 EX-10.2 Rani Therapeutics Holdings, Inc. 2026 Equity Inducement Plan Adopted by the Board of Directors: June 28, 2026 1) General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals

Rani Therapeutics Holdings Inc's ( NYSE:RANI ) short interest as a percent of float has risen 129.41% since its last report. According to exchange reported data, there are now 149 thousand shares sold short, which is 0.39% of all regular shares that are available for trading.

Rani Therapeutics Holdings, Inc. ( NASDAQ:RANI ) stock surged Friday after unveiling two major announcements: a licensing collaboration with Chugai Pharmaceutical Co., Ltd., and a $60.3 million private placement financing led by Samsara BioCapital.

Financing led by Samsara BioCapital, L.P. ( "Samsara" ) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir Imran

Rani Therapeutics ( NASDAQ:RANI ) , a biotech company developing oral biologic drug delivery technology, released its earnings for the second quarter of fiscal 2025 on August 7, 2025. Marking an improvement from the prior year period's $ ( 0.26 ) GAAP result.